FDA
-
-
-
-
-
-
-
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
-
-
-
-
-
-
-
Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
-
-
-
-
-
-
-
Vertex Pharma (VRTX) Reports Positive CHMP Opinion for CASGEVY
-
-
-
-
-
-
-
FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease (CRSP) (VRTX) (BLUE)
-
-
-
-
-
-
-
Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting
-
-
-
-
-
-
-
Vertex Pharma (VRTX) Announces FDA Approval of KALYDECO
-
-
-
-
-
-
-
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Th
-
251,888 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All